Sec Form 4 Filing - New Leaf Venture Management III, L.L.C. @ Deciphera Pharmaceuticals, Inc. - 2019-08-15

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person New Leaf Venture Management III, L.L.C. 2. Issuer Name and Ticker or Trading Symbol Deciphera Pharmaceuticals, Inc. [ DCPH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O NEW LEAF VENTURES, 420 LEXINGTON AVENUE, SUITE 408 3. Date of Earliest Transaction (MM/DD/YY) 08/15/2019 (Street) NEW YORK, NY10170 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/15/2019 S 71,550 D $ 36.0911 ( 1 ) 1,886,282 I See Footnote ( 2 ) ( 3 ) Common Stock 08/16/2019 S 69,292 D $ 36.5433 ( 4 ) 1,816,990 I See Footnote ( 2 ) ( 3 ) Common Stock 08/16/2019 S 26,108 D $ 37.0148 ( 5 ) 1,790,882 I See Footnote ( 2 ) ( 3 ) Common Stock 08/15/2019 S 78,450 D $ 36.0911 ( 1 ) 2,067,858 I See Footnote ( 6 ) ( 7 ) Common Stock 08/16/2019 S 75,974 D $ 36.5433 ( 4 ) 1,991,884 I See Footnote ( 6 ) ( 7 ) Common Stock 08/16/2019 S 28,626 D $ 37.0148 ( 5 ) 1,963,258 I See Footnote ( 6 ) ( 7 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other New Leaf Venture Management III, L.L.C. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK, NY10170 X New Leaf Ventures III, L.P. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK, NY10170 X New Leaf Biopharma Opportunities I, L.P. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK, NY10170 X New Leaf Venture Associates III, L.P. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK, NY10170 X New Leaf BPO Associates I, L.P. C/O NEW LEAF VENTURES 420 LEXINGTON AVENUE, SUITE 408 NEW YORK, NY10170 X Signatures /s/ Craig Slutzkin, attorney-in-fact for New Leaf Ventures III, L.P. 08/19/2019 Signature of Reporting Person Date /s/ Craig Slutzkin, attorney-in-fact for New Leaf Biopharma Opportunities I, L.P. 08/19/2019 Signature of Reporting Person Date /s/ Craig Slutzkin, attorney-in-fact for New Leaf Venture Associates III, L.P. 08/19/2019 Signature of Reporting Person Date /s/ Craig Slutzkin, attorney-in-fact for New Leaf BPO Associates I, L.P. 08/19/2019 Signature of Reporting Person Date /s/ Craig Slutzkin, attorney-in-fact for New Leaf Venture Management III, L.L.C. 08/19/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. ( 2 )The reportable securities are owned directly by New Leaf Ventures III, L.P. ("NLV III"). New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. ( 3 )(Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. ( 4 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. ( 5 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. ( 6 )The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. ( 7 )(Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.